Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.

Choose NJ’s RFP Watch

Choose New Jersey’s RFP Watch provides up-to-date information on business opportunities throughout the Garden State at a cost that is affordable for all companies – with a place of business in New Jersey – large and small.

To learn more click here

Poll Respondents Appreciate Innovation’s Economic, Social Benefits And Call For More Protections

Washington, DC, November 30, 2017Mark Grayson, deputy vice president of public affairs at the Pharmaceutical Research and Manufacturers of America (PhRMA), posts on the association’s blog, The Catalyst, that, increasingly, economists and international organizations are recognizing innovation as one of the most important drivers of economic and social progress and stability.

In fact, a report released earlier this year from the Global Intellectual Property Center, declared a robust innovation environment as “essential to the success of any 21st century economy.”

However, Grayson says it’s not just think tanks and academics acknowledging the value of innovation — the public is as well.

Grayson points out that in a recent U.S. poll on trade and innovation conducted by Morning Consult, 94 percent of respondents believe invention and innovations are somewhat or very important to the economy—and nearly three-quarters said they were “very important.”

When asked about which industries were perceived as most innovative, the technology industry is seen as the leader in innovation, followed by biopharma, agriculture and manufacturing.

Survey findings also indicate that Americans not only understand which industries bring innovative products and processes to the public, they also recognize the importance of protecting these industries and U.S. innovation more generally.

When asked about other countries using American inventions without properly compensating the inventor, the majority of respondents believe this harms the economy (70 percent), is detrimental to American inventors and entrepreneurs (70 percent) and harms American workers (70 percent), companies (68 percent) and job creation (66 percent).

With these implications in mind, Grayson writes that respondents want the U.S. to take further steps to protect innovation.

Two-thirds would like the U.S. to do more to prevent other countries from using inventions without proper compensation, and 68 percent want more on preventing other countries from infringing on trade deals that put inventions at risk from being stolen.

Eighty-three percent think if trading partners in other countries don’t play by the rules, the U.S. should hold them accountable.

It’s clear that experts and the general public alike understand the value of innovation and want to ensure that it is properly protected.

Grayson concludes that it is critical that policymakers and international leaders account for this and take steps to ensure innovation and innovative industries are supported and safeguarded from both domestic and international threats.

The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier and more productive lives.

Since 2000, PhRMA member companies have invested more than half a trillion dollars in the search for new treatments and cures, including an estimated $58.8 billion in 2015 alone.